BNT171 first candidate from BioNTech/Genevant collaboration | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34961 of 34995  at  11/21/2020 3:39:57 PM  by

liuyiiv


BNT171 first candidate from BioNTech/Genevant collaboration

It is listed here in BNTX pipeline

 
 https://biontech.de/science/pipeline
 
Also From BioNTech Form S1 IPO paper
 
Our Rare Disease Protein Replacement mRNA Product Candidates
We are collaborating with Genevant, in order to combine our mRNA technology with Genevant’s LNP delivery technology, to create up to five mRNA protein replacement therapies for the treatment of rare diseases with high unmet medical needs. We expect our first compound from this collaboration to enter the clinic by the second half of 2020. The first product candidate under the Genevant collaboration, BNT171, is currently being developed for an undisclosed indication. Our mRNA replacement product candidate is associated with a favorable tolerability profile and good protein expression (in mice) and demonstrated phenotype rescue in a mouse disease model.
 




     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
34962 Re: BNT171 first candidate from BioNTech/Genevant collaboration liuyiiv 0 11/22/2020 10:37:33 AM








Financial Market Data provided by
.
Loading...